Setara Biosciences’ lead program is a potential treatment for the rare neuromuscular disorder Charcot-Marie-Tooth disease type 2C and the prevalent condition overactive bladder. This small molecule came from Actio Biosciences, which was recently acquired by Jazz Pharmaceuticals.
The post Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the Clinic appeared first on MedCity News.
